Myasthenia is a recognised, albeit uncommon, complication of penicillamine therapy.' The majority of cases of this supposedly immune-mediated side effect have arisen when penicillamine is employed in the treatment of rheumatoid arthritis.' However, isolated cases have occurred in association with the treatment of Wilson's disease,2 3 progressive systemic sclerosis,4 and primary biliary cirrhosis.5 Penicillamine-induced myasthenia (PIM), while being dependent on penicillamine for its development and progression,' closely resembles spontaneous-onset myasthenia gravis clinically and in the accompanying presence of antibodies directed against acetylcholine receptors and/or striated muscle.6
Myasthenia is a recognised, albeit uncommon, complication of penicillamine therapy. ' The majority of cases of this supposedly immune-mediated side effect have arisen when penicillamine is employed in the treatment of rheumatoid arthritis.' However, isolated cases have occurred in association with the treatment of Wilson's disease,2 3 progressive systemic sclerosis,4 and primary biliary cirrhosis.5 Penicillamine-induced myasthenia (PIM), while being dependent on penicillamine for its development and progression,' closely resembles spontaneous-onset myasthenia gravis clinically and in the accompanying presence of antibodies directed against acetylcholine receptors and/or striated muscle. 6 The role of constitutional factors in the aetiology of spontaneous-onset myasthenia gravis and the development of immune-mediated manifestations of drug toxicity has recently aroused great interest. A genetic predisposition to the development of hydralazine-induced systemic lupus erythematosus,7 parenteral gold-induced nephropathy,' and sociated with thymic hyperplasia9-l' has been inferred from the abnormal distribution of HLA antigens observed in these 3 pathological states.
We have investigated the possibility that a genetic factor, determined by a locus or loci situated within the major histo-compatibility complex (MHC) of chromosome 6, might influence the development and/or expression of PIM. The HLA A, B, and Dr type together with the alleles of the complement components C2, C4, and factor B (which are controlled by loci in close proximity to those of HLA B and Dr) were ascertained in patients with rheumatoid arthritis who had developed a penicillaminedependent myasthenia.
Patients and methods
Eighteen previously unreported Caucasian patients (4M: 14F) who developed PIM during the period August 1978 to December 1981 were studied. All suffered with classical or definite rheumatoid arthritis as defined by the American Rheumatism Association criteria. Patient data together with details of penicillamine therapy and duration of rheumatoid arthritis at the onset of myasthenic symptoms appear in Table 1 . 500 16 Statistical methods. Significance was determined by The aetiology of this distressing and occasionally fatal manifestation of penicillamine toxicity remains obscure. However, the suggestion that penicillamine might in some undetermined manner unveil latent myasthenia gravis has been the subject of debate."72
The data arising from our study do not support this suggestion. HLA typing in the PIM subjects revealed a significant increase in HLA Dr 1 and an absence of HLA Dr 3. These findings argue that subjects developing PIM possess a different genetic background from those suffering spontaneous-onset myasthenia (in the absence of a thymoma), where the incidence of HLA Dr 3 is increased and that of HLA Dr 1 is normal.9'-They also appear to differ genetically from Caucasian rheumatoid patients in general, in whom HLA Dr 4 is increased but the incidence of HLA Dr 1 is unaltered.21-23
The literature contains reports of 6 other cases of PIM complicating rheumatoid arthritis in which HLA A, B, and Dr typing has been performed.6 2 24 25 Four cases were HLA Dr 1, while one was HLA Dr 3.2 The myasthenia in this last case was, however, atypical in the absence of antiacetylcholine receptor antibodies and, more importantly, in the recurrence of myasthenia 6 months after its initial complete resolution and 8 months afterpenicillamine had been withdrawn, a course that makes a druginduced aetiology unlikely. The absence of HLA Dr 3 in our study might reflect the increase in HLA Dr 1 which was observed in 62 % of our patients as compared with 17% of controls. An alternative explanation for this apparent loss of the normal linkage disequilibrium between HLA B8 and Dr 3 would be the conferment of resistance to the development of PIM by the HLA B8 Dr 3 haplotype.
Two of our 5 HLA B8 subjects were BfFF, as opposed to none of 100 normal HLA B8 subjects investigated by Arnason et 
